Navigation Links
New Study Shows Proprietary Canola Extract, Dermytol(TM), Produces Pronounced Decrease in Malignant Melanoma Tumor Volume
Date:4/7/2008

KGK Synergize Inc. Presents Findings Today

SAN DIEGO, April 7, 2008 /PRNewswire/ -- A new study presented at the Experimental Biology Annual Meeting shows that a proprietary blend extracted from canola, Dermytol(TM), produces a pronounced reduction of malignant melanoma cell growth. Dermytol(TM), a proprietary compound developed by KGK Synergize Inc., a biotechnology company in Ontario Canada, is designed to protect skin cells from damage that may lead to skin cancer.

Mal Evans, DVM, MSc, PhD, KGK Synergize Inc.'s Scientific Director, said, "Skin cancer rates have been rising, and we are likely to see that continue as the population ages. The National Cancer Institute (NCI) estimates that more than 62,000 Americans will be diagnosed with melanoma and one million Americans will be diagnosed with non-melanoma skin cancer this year. NCI expects more than 8,000 deaths from melanoma and less than 1,000 deaths from non-melanoma cancers this year.

"Dermytol(TM) has the potential to be used in anti-aging and sun-protection products to reduce damage to skin. Results of preclinical trials in animals have been promising leading to human trials now running in both Canada and the United States.

In the most recent study, male mice were fed either a Dermytol(TM)-canola oil mixture or just canola oil. In a separate part of the study, researchers applied either a Dermytol(TM) cream or a placebo cream onto the shaved skin of a different group of mice. After seven days of treatment, all of the mice were injected with malignant melanoma tumor cells. Dermytol(TM) or placebo treatments continued for 25 days.

The mice in both Dermytol(TM) groups benefited from their treatments. Compared to the controls, the orally treated mice showed an average decrease in tumor size by about 45 percent. The mice receiving the topical treatment benefited even more with a 61 percent decrease in tumor volume.

In this study and previous preclinical studies, Dermytol(TM) produced no adverse effects.

In a laboratory cell culture study, Dermytol(TM) inhibited the proliferation of human cancer cells.

In another study, dietary supplementation with Dermytol(TM) moderately delayed the onset of skin tumors and significantly reduced tumor growth rate in mice treated to induce non-melanoma skin cancers.

A trial involving 45 subjects with actinic keratoses -- precancerous skin lesions -- is underway. "The current treatment for actinic keratoses is removal by freezing which can be painful or the application of a cream that causes inflammation and blistering of the skin," said Evans. "We expect Dermytol(TM) to be a welcome option."

About KGK Synergize Inc:

KGK Synergize provides contract research services to the health nutrition, biotechnology and pharmaceutical industries which include analytical chemistry, in vitro assays, in vivo models, toxicology and human clinical trials.

In addition to its contract research capabilities, KGK has a Product Development Division, which brings new and innovative natural health products to the point where they are ready to be manufactured and marketed. These products include Sytrinol(TM) for cardiovascular health, Diabetinol(TM) for the treatment and/or prevention of Type II Diabetes, and Dermytol(TM), a new product for the protection of sun damage to the skin.


'/>"/>
SOURCE KGK Synergize Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. UltraShape(R) Non-Invasive Fat Reduction and Body Contouring Clinical Study Results Featured at American Society for Laser Medicine and Surgery Meeting
2. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
3. EnVivo Pharmaceuticals Announces Initiation of Clinical Safety and Biomarker Study of Alpha-7 Nicotinic Agonist, EVP-6124, in Patients with Schizophrenia
4. Study Finds Taxus(R) Drug-Eluting Stent Beneficial in Treatment of Large Vessels
5. Longevinex(R) Found to be Superior to Green Tea Molecule in Independent Human Study
6. Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer
7. Ranolazine Shortens QT Interval and Improves Cardiac Relaxation in Study of Patients With Genetic Sodium Channel Disorder
8. Large Study Gives Nod to Drug-Eluting Stents in Heart Attack
9. Study Finds Repeated Episodes of Stent Thrombosis Common
10. Study Finds PCI Safe, Effective Despite Off-Site Cardiac Surgery
11. Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... SPRING, Md. and RESEARCH TRIANGLE ... United Therapeutics Corporation (NASDAQ: UTHR ) announced ... financial results before the market opens on Thursday, July ... Therapeutics will host a teleconference on Thursday, July 27, ... accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533.  ...
(Date:7/19/2017)... 19, 2017  Mako Medical Laboratories partnered with Secretary ... Family Assistance Fund (MFA) to bring 140 soldiers back ... with their families one last time before being deployed. ... travel and logistics needed for these soldiers. "Mako Medical ... their families. We just wish we could bring them ...
(Date:7/14/2017)... July 13, 2017 It should come as no ... is in the midst of a crippling opioid epidemic. ... 1999, the number of overdose deaths from opiate-based medications has ... half a million dead from 2001 to 2015". During this ... hydrocodone has similarly quadrupled, drawing a compelling link between prescription ...
Breaking Medicine Technology:
(Date:7/26/2017)... (PRWEB) , ... July 26, 2017 , ... Six greater Bay Area roller derby leagues ... “Make ‘em Bleed,” the most widely attended series of blood drives in California, beginning July ... blood over the past 4 years -- enough to have helped to save up to ...
(Date:7/26/2017)... (PRWEB) , ... July 26, ... ... for Pharmaceutical Engineering (ISPE) will host its 2017 Process Validation and ... concurrent events offer comprehensive solutions to process validation lifecycle challenges faced by ...
(Date:7/26/2017)... ... July 26, 2017 , ... ... has opened in Jupiter. The state of the art center will provide ... treatments with a goal of providing heart patients longer lives. , North American ...
(Date:7/26/2017)... ... July 26, 2017 , ... ... specialty pharmacies, has released an updated version of the HCV Treatment Path app ... treating chronic hepatitis C virus (HCV) infection. All of the latest HCV medications ...
(Date:7/25/2017)... ... July 25, 2017 , ... Creative Pharmacist and ... provide the Pharmacist eCare Plan to Computer-Rx pharmacies through the STRAND ... ability to develop the Pharmacist eCare Plan, a shared document detailing a patient’s ...
Breaking Medicine News(10 mins):